Key Findings:  The authors describe a growing number of trials focusing on cannabimimetic ligands, that can act as CBR agonists or antagonist, or ECS enzyme inhibitors including terpenes such as β-caryophyllene, limonene, and terpineol for example, which may play a significant role in the modulation of different pathological conditions.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Brazil, Italy, United States
Year of Pub:  2020
Cannabinoids Studied: 
Phytocannabinoid Source:  Not Applicable
Terpenes Studied:  ß-Caryophyllene, Limonene, Terpineol
Receptors Studied:  CB2